Harmony Historical Income Statement

HRMY Stock

USD 33.23 0.44 1.34%

Historical analysis of Harmony Biosciences income statement accounts such as Interest Expense of 17.9 M or Selling General Administrative of 60.8 M can show how well Harmony Biosciences Holdings performed in making a profits. Evaluating Harmony Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Harmony Biosciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Harmony Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Harmony Biosciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harmony Biosciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Harmony Income Statement Analysis

Harmony Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Harmony Biosciences shareholders. The income statement also shows Harmony investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Harmony Biosciences Income Statement Chart

At this time, Harmony Biosciences' Net Income is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 46.8 M in 2024, whereas Net Interest Income is likely to drop (12.5 M) in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Reconciled Depreciation Net Income Applicable To Common Shares

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Harmony Biosciences. It is also known as Harmony Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Harmony Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Harmony Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harmony Biosciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	18.8M	23.4M	24.3M	14.7M
Total Operating Expenses	162.4M	234.2M	268.8M	178.2M

Reconciled Depreciation Total Operating Expenses

Harmony Biosciences income statement Correlations

	Net Interest Income	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Non Operating Income Net Other	Interest Income
Net Interest Income		-0.78	-0.74	-0.8	-0.7	-0.55	-0.46	-0.55	-0.49	-0.57	-0.71	-0.79	-0.44	0.97	-0.43	-0.03	-0.38	-0.3
Depreciation And Amortization	-0.78		0.99	0.98	0.97	0.85	0.84	0.86	0.78	0.87	0.95	1.0	0.8	-0.68	0.82	-0.04	0.8	0.64
Selling General Administrative	-0.74	0.99		0.99	1.0	0.82	0.8	0.83	0.87	0.84	0.99	0.99	0.78	-0.61	0.78	0.01	0.83	0.69
Selling And Marketing Expenses	-0.8	0.98	0.99		0.99	0.8	0.76	0.8	0.85	0.82	0.98	0.98	0.75	-0.69	0.73	0.09	0.79	0.69
Other Operating Expenses	-0.7	0.97	1.0	0.99		0.81	0.79	0.81	0.89	0.83	0.99	0.97	0.77	-0.57	0.77	0.04	0.84	0.72
Operating Income	-0.55	0.85	0.82	0.8	0.81		0.96	1.0	0.56	1.0	0.76	0.85	0.99	-0.47	0.94	0.2	0.88	0.85
Net Income From Continuing Ops	-0.46	0.84	0.8	0.76	0.79	0.96		0.96	0.57	0.96	0.74	0.84	0.97	-0.34	1.0	-0.05	0.92	0.76
Ebit	-0.55	0.86	0.83	0.8	0.81	1.0	0.96		0.55	1.0	0.76	0.86	0.99	-0.47	0.94	0.19	0.87	0.84
Research Development	-0.49	0.78	0.87	0.85	0.89	0.56	0.57	0.55		0.58	0.93	0.78	0.53	-0.31	0.54	-0.02	0.78	0.64
Ebitda	-0.57	0.87	0.84	0.82	0.83	1.0	0.96	1.0	0.58		0.78	0.87	0.99	-0.49	0.94	0.18	0.87	0.84
Total Operating Expenses	-0.71	0.95	0.99	0.98	0.99	0.76	0.74	0.76	0.93	0.78		0.95	0.72	-0.57	0.71	0.03	0.82	0.7
Reconciled Depreciation	-0.79	1.0	0.99	0.98	0.97	0.85	0.84	0.86	0.78	0.87	0.95		0.8	-0.68	0.82	-0.04	0.8	0.64
Income Before Tax	-0.44	0.8	0.78	0.75	0.77	0.99	0.97	0.99	0.53	0.99	0.72	0.8		-0.35	0.95	0.19	0.9	0.87
Total Other Income Expense Net	0.97	-0.68	-0.61	-0.69	-0.57	-0.47	-0.34	-0.47	-0.31	-0.49	-0.57	-0.68	-0.35		-0.31	-0.14	-0.21	-0.21
Net Income	-0.43	0.82	0.78	0.73	0.77	0.94	1.0	0.94	0.54	0.94	0.71	0.82	0.95	-0.31		-0.11	0.9	0.72
Income Tax Expense	-0.03	-0.04	0.01	0.09	0.04	0.2	-0.05	0.19	-0.02	0.18	0.03	-0.04	0.19	-0.14	-0.11		0.03	0.52
Non Operating Income Net Other	-0.38	0.8	0.83	0.79	0.84	0.88	0.92	0.87	0.78	0.87	0.82	0.8	0.9	-0.21	0.9	0.03		0.87
Interest Income	-0.3	0.64	0.69	0.69	0.72	0.85	0.76	0.84	0.64	0.84	0.7	0.64	0.87	-0.21	0.72	0.52	0.87

Click cells to compare fundamentals

Harmony Biosciences Account Relationship Matchups

Harmony Biosciences income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	(6.1M)	(28.2M)	(24.0M)	(15.7M)	(11.9M)	(12.5M)
Depreciation And Amortization	3.2M	10.2M	18.8M	23.4M	24.4M	14.7M
Interest Expense	6.1M	28.2M	24.0M	15.7M	23.8M	17.9M
Selling General Administrative	36.4M	39.7M	63.9M	84.0M	95.3M	60.8M
Selling And Marketing Expenses	44.3M	55.8M	68.1M	79.3M	97.4M	66.3M
Total Revenue	6.0M	159.7M	305.4M	437.9M	582.0M	611.1M
Gross Profit	4.4M	132.0M	249.9M	354.4M	460.8M	483.8M
Other Operating Expenses	151.9M	142.8M	217.9M	317.7M	390.0M	231.3M
Operating Income	(145.9M)	3.7M	68.7M	120.2M	192.0M	201.6M
Net Income From Continuing Ops	(152.0M)	(36.9M)	34.6M	181.5M	150.8M	158.3M
Ebit	(145.9M)	(8.7M)	87.5M	120.2M	192.0M	201.6M
Research Development	69.6M	19.4M	30.4M	70.9M	76.1M	51.1M
Ebitda	(142.7M)	1.5M	106.4M	143.6M	216.4M	227.2M
Cost Of Revenue	1.6M	27.7M	55.5M	83.5M	121.2M	127.3M
Total Operating Expenses	150.3M	115.0M	162.4M	234.2M	268.8M	178.2M
Reconciled Depreciation	3.2M	10.2M	18.8M	23.4M	24.3M	14.7M
Income Before Tax	(152.0M)	(36.9M)	37.4M	104.7M	173.4M	182.1M
Total Other Income Expense Net	(6.1M)	(53.9M)	(50.1M)	(15.5M)	(18.6M)	(19.6M)
Net Income Applicable To Common Shares	(187.2M)	(63.8M)	34.6M	181.5M	208.7M	219.1M
Net Income	(158.1M)	(51.9M)	34.6M	181.5M	128.9M	135.3M
Income Tax Expense	6.1M	14.9M	2.8M	(76.8M)	44.5M	46.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Harmony Historical Income Statement

About Harmony Income Statement Analysis

Harmony Biosciences Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Net Income Applicable To Common Shares

Harmony Biosciences income statement Correlations

Harmony Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Harmony Biosciences income statement Accounts

Also Currently Popular

Additional Tools for Harmony Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Tax Provision	Net Interest Income
Depreciation And Amortization	Interest Expense
Selling General Administrative	Selling And Marketing Expenses
Total Revenue	Gross Profit
Other Operating Expenses	Operating Income
Net Income From Continuing Ops	Ebit
Research Development	Ebitda
Cost Of Revenue	Total Operating Expenses
Reconciled Depreciation	Income Before Tax
Total Other Income Expense Net	Net Income Applicable To Common Shares
Net Income	Income Tax Expense
Preferred Stock And Other Adjustments	Non Operating Income Net Other
Interest Income

Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Other Operating Expenses	+ 1.0	Selling General Administrative
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Net Income	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit

Selling And Marketing Expenses	- 0.8	Net Interest Income
Reconciled Depreciation	- 0.79	Net Interest Income
Depreciation And Amortization	- 0.78	Net Interest Income
Selling General Administrative	- 0.74	Net Interest Income
Total Operating Expenses	- 0.71	Net Interest Income
Other Operating Expenses	- 0.7	Net Interest Income